Wrapping up our CBCT users market research, we studied the software usage of a random sample of 300 CBCT users. Although it wasn't a surprise that the rates of each software's usage is directly related to its CBCT machine's popularity in the market, yet, some specific softwares managed to break the rule and to form itself a massive users market in a field it excels in.
The first step to create a product that pleases one's audience is to know one's audience.
This second part of our extensive CBCT user's market research is focusing on the user's specialty.
And the results say it loud and clear: Maybe it's time for a more "custom designed" CBCT experience for the different strata of users.
On our study conducted over 300 random CBCT users. We had a special entry about what speciality tends to use CBCT more. Participants had to attribute 1 of 5 ranks for each speciality according to the frequency of use.
Following the bird's eye view of the CBCT users market research, we present an in-depth look at some of the users' comments on different CBCT machines available in the market.
We received feedback from over 300 CBCT machine owners and will begin by giving a rough bird's eyes view of the CBCT machines ownership stats.
As a response to our past poll on the real relevance of CBCT in the dental field, some of our contributors seemed to have a hard time getting to introduce CBCT to a rather skeptical dental market:
An argument is going on now about re-imbursements for CBCT scans. That issue is coming up with increasing urgency as more doctors equip their offices with this cutting-edge technology.
A new technology is changing the way a general dentist or specialist looks at patients - literally.
No longer do they need to rely only on two dimensional x-rays for diagnosis, treatment planning and patient education. X-rays now come in three and even four dimensions, including manipulation of those images with new programs.
Recent paper has concluded that the NewTom 3G CBCT had a lower diagnostic accuracy for detection of caries lesions than intraoral modalities and the 3DX Accuitomo CBCT. The Accuitomo CBCT had a higher sensitivity than the intraoral systems for detection of lesions in dentin, but the overall true score was not higher.
Materialise N.V. and Materialise Dental N.V., manufacturer of 3D implant planning systems, have launched a U.S. patent infringement lawsuit in the Central District of California against Nobel Biocare, AB and its U.S. subsidiary Nobel Biocare USA. LLC. Specifically, Materialise contends that Nobel Biocare’s manufacture of “NobelGuide” drilling template violates a Materialise U.S. patent that was issued in 1998 relating to Materialise’s “SurgiGuide” techniques.